Sign In
Buy GKOS
$113.64
+2.86 (+2.58%)
At Close: Jun 03, 2026
Ameritas Investment Partners Inc. Has $590,000 Holdings in Glaukos Corporation $GKOS
03:26am, Saturday, 29'th Nov 2025
Ameritas Investment Partners Inc. boosted its stake in Glaukos Corporation (NYSE: GKOS) by 14.0% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commiss
Here's Why You Should Retain Glaukos Stock in Your Portfolio
01:46pm, Friday, 28'th Nov 2025
GKOS gains momentum from iDose TR's strong launch and a growing pipeline, though reimbursement hurdles pose challenges ahead.
Glaukos (GKOS) Up 20% Since Last Earnings Report: Can It Continue?
12:31pm, Friday, 28'th Nov 2025
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?
Creative Planning Has $1.90 Million Stock Holdings in Glaukos Corporation $GKOS
04:02am, Thursday, 27'th Nov 2025
Creative Planning raised its stake in Glaukos Corporation (NYSE: GKOS) by 28.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC
Glaukos Corporation (GKOS) Presents at UBS Global Healthcare Conference 2025 Transcript
01:21pm, Tuesday, 11'th Nov 2025
Glaukos Corporation ( GKOS ) UBS Global Healthcare Conference 2025 November 11, 2025 10:15 AM EST Company Participants Alex Thurman - Senior VP & CFO Christopher Lewis - Vice President of Investor Rel
Brown Capital Sells $35 Million in Glaukos Stock After Sharp Sell-Off
06:02am, Thursday, 06'th Nov 2025
Baltimore-based Brown Capital Management sold 376,359 shares of Glaukos Corporation for an estimated $34.6 million in the third quarter. The transaction value equaled approximately 1.4% of fund's 13F
Glaukos Corporation $GKOS Shares Acquired by Teacher Retirement System of Texas
04:31am, Tuesday, 04'th Nov 2025
Teacher Retirement System of Texas raised its position in shares of Glaukos Corporation (NYSE: GKOS) by 3.3% in the second quarter, according to its most recent Form 13F filing with the Securities and
Glaukos Announces Participation in Upcoming Investor Conferences
07:00am, Monday, 03'rd Nov 2025
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
Here's What Key Metrics Tell Us About Glaukos (GKOS) Q3 Earnings
05:20am, Monday, 03'rd Nov 2025
Although the revenue and EPS for Glaukos (GKOS) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Str
2,331 Shares in Glaukos Corporation $GKOS Acquired by Ethic Inc.
03:21am, Friday, 31'st Oct 2025
Ethic Inc. purchased a new position in shares of Glaukos Corporation (NYSE: GKOS) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor purchased
Why Glaukos Stock Zoomed Almost 14% Higher on Thursday
06:54pm, Thursday, 30'th Oct 2025
The biotech notched a new all-time high for net sales in its third quarter. This growth was powered by sales of its foundational glaucoma products.
GKOS Stock Surges Following Q3 Earnings & Revenue Beat, Guidance Raised
01:26pm, Thursday, 30'th Oct 2025
Glaukos reported a narrower Q3 loss, strong 38% sales jump, and raised 2025 outlook as iDose TR and Epioxa fuel momentum across key franchises.
State of New Jersey Common Pension Fund D Buys 800 Shares of Glaukos Corporation $GKOS
05:50am, Thursday, 30'th Oct 2025
State of New Jersey Common Pension Fund D boosted its stake in Glaukos Corporation (NYSE: GKOS) by 4.2% during the undefined quarter, according to the company in its most recent disclosure with the Se
Glaukos Corporation (GKOS) Q3 2025 Earnings Call Transcript
12:06am, Thursday, 30'th Oct 2025
Glaukos Corporation ( GKOS ) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Christopher Lewis - Vice President of Investor Relations & Corporate Affairs Thomas Burns - Chairma
Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates
06:56pm, Wednesday, 29'th Oct 2025
Glaukos (GKOS) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.28 per share a year ago.
